Related Experiment Videos
T-cell-targeted immunofusion proteins from E. coli
1XOMA Corporation, Santa Monica, California 90404, USA.
Annals of the New York Academy of Sciences
|May 15, 1996
Summary
Researchers developed novel immunofusion proteins by linking H65 antibody domains to gelonin for targeted T-cell therapy. These engineered proteins were successfully produced and purified from E. coli, showing potential as therapeutic agents.
Area of Science:
- Biotechnology
- Molecular Biology
- Immunology
Background:
- Antibodies and antibody domains are effective for cell targeting.
- Fusion proteins combining targeting and cytotoxic elements offer therapeutic potential.
Purpose of the Study:
- To construct and express immunofusion proteins linking H65 antibody domains (targeting CD5 antigen on T cells) with gelonin (a cytotoxic protein).
- To develop an efficient microbial production system for these novel therapeutic agents.
Main Methods:
- Assembled over 30 fusion genes encoding various combinations of H65 antibody domains and gelonin.
- Utilized bacterial signal sequences for secretion and expression in E. coli.
- Employed fermentation and column chromatography for protein purification.
Main Results:
- All immunofusion proteins were secreted, folded correctly, and active in the bacterial culture supernatant.
- Purification was achieved through a single chromatographic process.
- The immunofusion proteins demonstrated cytotoxicity against antigen-positive human cells.
Conclusions:
- An integrated microbial production system was established for manufacturing immunofusion proteins.
- These engineered fusion proteins show promise as targeted cytotoxic therapeutics.